Go back

Qdossier Qsauri
"C"

complete response letter
Guideline or reference source
FDAGDUFA Generic Drug User Fee Amendments 2012
Definition
a written communication to an applicant or DMF holder from FDA usually describing all of the deficiencies that the agency has identified in an abbreviated application (including pending amendments) or a DMF that must be satisfactorily addressed before the ANDA can be approved. Complete response letters will reflect a complete review and will require a complete response from industry to restart the clock. Refer to 21 CFR 314.110 and http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/LawsActsandRules/ucm084138.htm1 for additional details. When a citizen petition may impact the approvability of the ANDA, FDA will strive to address, where possible, valid issues raised in a relevant citizen petition in the complete response letter. If a citizen petition raises an issue that would delay only part of a complete response, a response that addresses all other issues will be considered a complete response.
Related Term
act on application
first major deficiency application
solicited amendment
 

Send comments to info@qdossier.com Please read disclaimer before using Qsauri.